Moreover, the researchers evaluated the mutational profile of MPN patients using next-generation sequencing in both DNA samples extracted from granulocytes and cfDNA and evidenced that cfDNA was as accurate as granulocyte DNA for the detection of driver (JAK2, CALR, MPL) and non-driver (TET2, ASXL1, IDH2, DNMT3A, SF3B1, SRSF2, etc.)mutations. This evidence concerns the gene TET2 and myeloproliferative disorder.